ARTICLE | Company News
Atara gains on breakthrough designation
March 3, 2015 1:42 AM UTC
Atara Biotherapeutics Inc. (NASDAQ:ATRA) gained $0.92 to $20.48 after its partner, Memorial Sloan Kettering Cancer Center, received breakthrough therapy designation for EBV-CTL to treat rituximab-refractory lymphoproliferative disease associated with Epstein-Barr virus (EBV), which can occur after allogeneic hematopoietic cell transplantation (HCT). ...